Xavier Morelli Group Leader in Structure-Based Drug Design - CRCM Marseille
Course and current status
Research Director (DR2), CNRS
Group Leader – Cancer Research Center of Marseille (CRCM)
Targeting Protein-Protein interaction in cancer signaling & Epigenetics using integrated structural & chemical biology
Member of the National Academic Screening Platforms ‘AD2P’
In charge of the Chemoinformatics (Chemical Libraries Selection), Hit validation - Hitto Lead optimization
Secretary of the French Society of ChemoInformatics (SFCi)
Scientific committee member of the National Foundation ‘ARC’ (national agency against cancer)
Board of expert at the French Society of Medicinal Chemistry
Board of expert at the ‘Epigenetics’ AVIESAN consortium (French Minister of Research).
Board of expert at the Aix-Marseille University PhD Doctoral School of Chemistry
Associate Editor of the Scientific Journal “BMC Pharmacology & Toxicology”
Regular Consultant for pharmaceutical companies since 2009
11 Grants as coordinator or participant (5 running)
May 2008 Habilitation à Diriger des Recherches - Aix-Marseille University
1997-2000 PhD, University of PARIS XI
Dr. Mireille Bruschi’s Laboratory, (UPR9036 - Marseille, France).PhD Advisor: Dr. Françoise Guerlesquin
1995-1996 Master’s Degree - Universityof ParisXI
Crystallography and Biological NMR, Concepts and Methods. (rank: 1st)
1994-1995Bachelor’s Degree – Aix-Marseille University
Biochemistry majoring in Biophysics (NMR, EPR, X-RAYS) (rank: 1st/76)
PresentResearch Director (DR2), CNRS.
Group Leader of the group iSCB ‘integrative Structural & Chemical Biology” at the Cancer Research Center of Marseille (CRCM, CNRS UMR7258 – INSERM U1068). 20 persons: 8 permanent researchers (3 DR2, 3 CR1, 1CR2 and 1 MCU), 1 technician in bioinformatics, 1 technician in organic chemistry, 2 technicians in biochemistry and cellular biology, 3 postdoctorates, 4 PhD students, 1 undergraduate student. Principal focus of the group:Identify, validate, understand and target protein-protein interaction in cancer cell signaling & epigenetic processes.
2008-2012 Group Leader of the group ID3 “Interaction, Dynamics and Drug Design” at the IMR laboratory (CNRS FRE3083) involving 12 persons: 3 permanent researchers (CR1), 1IT support, 1 technician in bio-informatics, 1 technician in biochemistry, 3 Post-doctorate and 3 PhD students.
2002 – 2007 Principal Investigator - CNRS (National Center for the Scientific Research) FRANCE.
2000-2002 Postdoctorate at Harvard Medical School (Pr Bruce Furie - Chief, Division of Hemostasis and Thrombosis, BIDMC).
STUDENT & POSTDOCTORAL MANAGEMENT *Thesis n=6 as PhD advisor *Postdoctorate n=5 as direct advisor
11 Grants as coordinator or participant (5 running):
- CNRS - Program 'PIR' (Coordinator): 2010- Aix-Marseille University - Fond Incitatif de Recherche 'FIR' (Coordinator): 2010- Fondation pour la Recherche Médicale - FRM (Coordinator): 2010/11- Private Grant from Pharmaceutical Company ‘ValiRX’ (Coordinator): 2010/11- Private Grant from Pharmaceutical Company ‘IdRS’ (Coordinator): 2010/11- INSERM Transfert ‘COPoC’ (Partner): 2013/14- Institut National du Cancer - INCa 'Program PAIR Prostate' (Partner): 2010/14- Région PACA (Partner): 2012/14 & 2015/17- ANR 'Program Blanc' (Partner): 2013/16- Institut National du Cancer - INCa 'Program PLBio' (Partner): 2013/17- Fondation ARC 'Programme Libre' (Partner): 2014/17- Program 'A*MIDEX' Aix-Marseille University (Partner): 2015-2017 CONSULTING / REVIEWING ACTIVITIES:
Expert for serveral National (ANR, French Ministry of Research, Region) and International (Neterland 'NWO', Singapore 'A*STAR', Ireland 'INA') agencies.
Expert / Consultant / Conference for several pharmaceutical companies (J&J, Merck-Serono, Tibotec, Hybrigenics, Institut de Recherche Servier, Laboratoires Fournier)
PUBLICATIONS: (H Index = 15)
50 Publications (3 submitted)
2 book chapters. 3 international patents (1 submitted).
50 INVITED CONFERENCES SINCE 2006 – 25 INTERNATIONAL, 25 NATIONAL